Solventum Co. (NYSE:SOLV) Shares Sold by Bradley Foster & Sargent Inc. CT

Bradley Foster & Sargent Inc. CT lessened its position in shares of Solventum Co. (NYSE:SOLV) by 7.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,764 shares of the company’s stock after selling 549 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Solventum were worth $447,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in SOLV. Trian Fund Management L.P. increased its holdings in Solventum by 32.9% during the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock valued at $496,842,000 after acquiring an additional 1,765,676 shares in the last quarter. State Street Corp increased its stake in shares of Solventum by 3.1% during the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock worth $425,818,000 after purchasing an additional 185,938 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Solventum by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 3,347,719 shares of the company’s stock worth $232,608,000 after purchasing an additional 128,317 shares during the last quarter. Hotchkis & Wiley Capital Management LLC purchased a new stake in Solventum in the 3rd quarter valued at approximately $125,488,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Solventum by 0.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,053,771 shares of the company’s stock valued at $73,469,000 after buying an additional 3,745 shares during the last quarter.

Wall Street Analyst Weigh In

SOLV has been the subject of a number of analyst reports. Morgan Stanley boosted their price target on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Mizuho began coverage on Solventum in a research report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price objective for the company. Finally, Piper Sandler upped their target price on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $68.29.

Solventum Stock Down 1.9 %

NYSE SOLV opened at $73.08 on Friday. The business’s 50-day moving average price is $71.14 and its 200 day moving average price is $69.15. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.